Results 21 to 30 of about 53,966 (218)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis [PDF]

, 2021
Aim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab.
Meireles, Angelina, Beirão, João Nuno Melo, Pessoa, Bernardete, Figueira, João, Melo Beirão, João Nuno, Figueira, João P, Coelho, João, Monteiro, Sílvia, Coelho, Constança, Beirão, João, Malheiro, Luísa, Carneiro, Inês, João Coelho, Luísa Malheiro, Angelina Meireles, Sílvia Monteiro, João Figueira, Bernardete Pessoa, Inês Carneiro, Constança Coelho, João Nuno Melo Beirão   +20 more
core   +1 more source

INTRAVITREAL BEVACIZUMAB FOR THE TREATMENT OF CHOROIDAL HEMANGIOMAS. [PDF]

Retina
Purpose: To investigate the use of intravitreal bevacizumab for the treatment of subretinal fluid (SRF) and intraretinal fluid associated with circumscribed choroidal hemangiomas. Methods: This was a retrospective review of all patients treated with at least three bevacizumab ...
Elkayal HE, Sagoo MS, Negretti GS.
europepmc   +3 more sources

Comparison of Intravitreal Bevacizumab versus Triamcinolone for the Treatment of Diffuse Diabetic Macular Edema [PDF]

, 2010
Background: Our purpose was to compare the effect of triamcinolone and bevacizumab (Avastin) on the retinal thickness and functional outcome in patients with diabetic macular edema. Methods and Materials: A collective of 32 patients, who had been treated
Haritoglou, Christos, Ulbig, Michael W., Kook, Daniel, Wolf, Armin, Neubauer, Aljoscha Steffen, Kreutzer, Thomas C., Al Saeidi, Rashid   +6 more
core   +1 more source

Intracameral Injection of Bevacizumab for the Treatment of Neovascular Glaucoma [PDF]

, 2011
Purpose: To assess the duration of the effect of intracameral bevacizumab in patients presenting with rubeosis iridis and neovascular glaucoma (NVG). Methods: Retrospective analysis of 24 consecutive eyes of 24 patients with decompensated NVG (> 21 mm Hg)
Haritoglou, Christos, Wolf, Armin, Ulbig, Michael, Christos Haritoglou, Jagow, Burkhard von, Burkhard von Jagow, Michael Ulbig, Armin Wolf   +7 more
core   +1 more source

Reflux after Intravitreal Injection of Bevacizumab [PDF]

Ophthalmology, 2008
Contains fulltext : 71203.pdf (Publisher’s version ) (Open Access)
Boon, C.J.F., Crama, N., Klevering, B.J., Kuijk, F.J. van, Hoyng, C.B.   +4 more
openaire   +2 more sources

Quality of bevacizumab compounded for intravitreal administration [PDF]

Eye, 2013
To compare the quality and stability of unlicensed, repackaged bevacizumab intended for intravitreal injection, as provided by five licensed compounding pharmacies in the United Kingdom, with bevacizumab in its original glass vial.Repackaged bevacizumab was obtained from five UK suppliers.
Palmer JM, Amoaku WM, Kamali F
openaire   +3 more sources

Comparison of Intravitreal Bevacizumab Upload Followed by a Dexamethasone Implant versus Dexamethasone Implant Monotherapy for Retinal Vein Occlusion with Macular Edema [PDF]

, 2012
Purpose: To compare the efficacy and safety of three intravitreal bevacizumab upload injections followed by a dexamethasone implant versus dexamethasone implant monotherapy in eyes with macular edema due to retinal vein occlusion.
Haritoglou, Christos, Mayer, Wolfgang J., Wolf, Armin, Kook, Daniel, Ulbig, Michael, Reznicek, Lukas, Remy, Matthias, Kampik, Anselm   +7 more
core   +1 more source

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI). [PDF]

Clin Exp Ophthalmol
ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021.
Wang H, Bahrami B, Huang S, Tahmasebi Sarvestani M, Cugati S, Lake S, Chan WO, Supramaniam D, Little M.   +8 more
europepmc   +3 more sources

Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab

Indian Journal of Ophthalmology, 2015
Aims: To evaluate the 1-month efficacy of intravitreal triamcinolone acetonide (TA) in treating macular edema secondary to retinal vein occlusion (RVO) that was refractory to intravitreal bevacizumab.
Seul Gi Yoo, Jae Hui Kim, Tae Gon Lee, Chul Gu Kim, Jong Woo Kim   +4 more
doaj   +1 more source

Pengaruh Bevacizumab Intravitreal terhadap Best Corrected Visual Acuity dan Central Macular Thickness pada Diabetic Macular Edema

Jurnal Kesehatan Andalas, 2020
Diabetic Macular Edema (DME) adalah penyebab utama kebutaan pada populasi diabetes. Salah satu patogenesis pada DME adalah karena peningkatan ekspresi VEGF.
Arini Ghaisa Atsari, Weni Helvinda
doaj   +1 more source